A Phase 1 interventional study of SNX-5422 Mesylate Hsp90 inhibitor in Solid Tumor Malignancy, Lymphoid Malignancy (Lymphoma and CLL) and Leukemia, sponsored by Esanex Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-05-17.
Sponsored by Esanex Inc. · Phase 1, Interventional, and Treatment
Hsp90 is a chemical in the body that is involved in promotion of cancer. SNX-5422 is an experimental drug that blocks Hsp90. It is being evaluated for safety and efficacy in patients with cancer.
5,578 studies on the registry are indexed under Lymphoma; 825 are open to participants now.
This study's enrollment of 32 is below the median of 40 across 4,508 interventional studies indexed under Lymphoma.
Browse Lymphoma studies →Esanex Inc. is the lead sponsor of 12 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: SNX-5422 Mesylate Hsp90 inhibitor
dose escalated, tablets twice a week; undetermined duration until disease progression
MTD, safety and toxicity
Time frame: continuous
pharmacokinetic profile of SNX-5422
Time frame: first cycle
tumor response measured by X-rays or scans
Time frame: after every 2 cycles
This study is completed, as verified in May 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Esanex Inc.